APA (7th ed.) Citation

Beysen, C., Schroeder, P., Wu, E., Brevard, J., Ribadeneira, M., Lu, W., . . . Kelly, P. F. (2021). Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials. Diabetes, obesity & metabolism, 23(3), 700-710. https://doi.org/10.1111/dom.14272

Chicago Style (17th ed.) Citation

Beysen, Carine, et al. "Inhibition of Fatty Acid Synthase with FT‐4101 Safely Reduces Hepatic De Novo Lipogenesis and Steatosis in Obese Subjects with Non‐alcoholic Fatty Liver Disease: Results from Two Early‐phase Randomized Trials." Diabetes, Obesity & Metabolism 23, no. 3 (2021): 700-710. https://doi.org/10.1111/dom.14272.

MLA (9th ed.) Citation

Beysen, Carine, et al. "Inhibition of Fatty Acid Synthase with FT‐4101 Safely Reduces Hepatic De Novo Lipogenesis and Steatosis in Obese Subjects with Non‐alcoholic Fatty Liver Disease: Results from Two Early‐phase Randomized Trials." Diabetes, Obesity & Metabolism, vol. 23, no. 3, 2021, pp. 700-710, https://doi.org/10.1111/dom.14272.